Document:

Exhibit 10.13

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #3 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case Nos: ***

 

    	 

    	 

    

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #3 TO:

EXCLUSIVE LICENSE FOR

***

 

UC Case Nos: ***

 

 

 

Effective March 25, 2003 (the
“EFFECTIVE DATE OF AMENDMENT #3”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose
legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of
Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620
(“REGENTS”) and KINEMED, INC., a Delaware corporation having a principal place of business at EmeryStation
North, 5980 Horton Street, Suite 470, Emeryville, CA 94608-2012 (“LICENSEE”), agree to amend that
certain Agreement between REGENTS and LICENSEE which bears an effective date of February 16, 2001 (as amended
previously through Amendment #1 and Amendment #2, said Amendments #1 and #2 bearing effective dates of June 15, 2002,
and October 15, 2002 respectively), as follows:,

 

ARTICLE 1.1 (m) (BACKGROUND) add the
following:

 

1.1 m) ***

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #3	Confidential

 

    	 

    	 

    

 

ARTICLE 2.1(j) (DEFINITIONS) substitute
the following:

 

(j) All of
Regents’ United States patent applications filed under U.C. Case Numbers .: *** as described in Article 1.1 (c) through
(m) above, and;

 

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(b) LICENSEE shall
also pay to REGENTS a non-creditable, non- refundable license fee of *** on or before *** and an additional non-creditable, non-refundable
license fee of *** on or before ***. In addition, LICENSEE shall, within *** days after the final execution of this amendment
#1 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS’ employee(s)
a total of *** shares of common stock in KineMed, Inc., in accordance with the Shareholder’s Agreements between REGENTS
and LICENSEE dated February 16, 2001 and June 11, 2002. As of the EFFECTIVE DATE OF AMENDMENT #2, REGENTS acknowledges that
LICENSEE has fully paid to REGENTS *** and *** shares of common stock in KineMed, Inc. in accordance with this Article 5.1(b).

 

As consideration for
the addition of REGENTS’ case *** by way of the second amendment to the Agreement, LICENSEE shall also pay to REGENTS a
non-creditable, non-refundable fee of *** on or before November 15, 2002 and shall, within *** days after the final
execution of this amendment #2 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater &
Co., and to REGENTS employee(s) a total of *** shares of common stock in

 

KineMed, Inc., in accordance with the Shareholder's
Agreements between

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #3	Confidential

 

    	 

    	 

    

 

REGENTS and LICENSEE attached hereto as Exhibit
A. As of the EFFECTIVE DATE OF AMENDMENT #3, REGENTS acknowledges that LICENSEE has fully paid to REGENTS *** and has issued
*** shares of common stock in KineMed, Inc. pursuant to the additional rights granted in the second amendment to the Agreement
and in accordance with this Article 5.1(b).

 

As consideration for
the addition of REGENTS' case *** by way of this third amendment to the Agreement, LICENSEE shall also pay to REGENTS a
non-creditable, non-refundable fee of *** on or before *** and shall, within *** days after the final execution of this
amendment #3 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS
employee(s) a total of *** shares of common stock in KineMed, Inc., in accordance with the Shareholder's Agreements
between REGENTS and LICENSEE attached hereto as Exhibit A.

 

ARTICLE 5.1(c) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(c) For any of
the following U.C. Case Numbers: *** as described in Article 2.1(j) and in Article 1.1 (c) through (m) above, if the
corresponding patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number,
LICENSEE shall be entitled to a credit of *** toward its future royalty payments to REGENTS pursuant to Article
6.1.

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #3	Confidential

 

    	 

    	 

    

 

All remaining terms and conditions of the
Agreement (as amended) remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE	 	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 	 
	 	 	 
	By	/s/ Carol Mimura	 	By	/s/ David M. Fineman
	 	Carol Mimura, Ph.D.	 	 	David M. Fineman
	 	Acting Director	 	 	President & CEO
	 	Office of Technology Licensing	 	 
	 	 	 
	Date April 3, 2003	 	Date April 1, 2003

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #3	ConfidentialExhibit 10.14

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #4 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case Nos: ***

 

    	 

    	 

    

  

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #4 TO:

EXCLUSIVE LICENSE FOR

***

 

UC Case Nos: ***

 

 

 

Effective November 6, 2003 (the “EFFECTIVE
DATE OF AMENDMENT #4”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111
Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at the University
of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620 (“REGENTS”) and KINEMED, INC., a
Delaware corporation having a principal place of business at EmeryStation North, 5980 Horton Street, Suite 470, Emeryville, CA
94608-2012 (“LICENSEE”), agree to amend that certain Agreement between REGENTS and LICENSEE which bears an effective
date of February 16, 2001 (as amended previously through Amendments #1, #2, and #3, said Amendments #1, #2, and #3 bearing effective
dates of June 15, 2002, October 15, 2002, and March 25, 2003, respectively), as follows:

 

ARTICLE 1.1 (n) (BACKGROUND) add the
following:

 

1.1 n) ***

 

1.1 o) ***

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #4	Page 1	Confidential

    	 

    

   

ARTICLE 2.1(j) (DEFINITIONS) substitute
the following:

 

(j) All of Regents' United
States patent applications filed under U.C. Case Numbers *** as described in Article 1.1 (c) through (o) above, and;

 

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(b) As of the EFFECTIVE
DATE OF AMENDMENT #4, REGENTS acknowledges the LICENSEE has fully paid to REGENTS all stock and cash license and amendment fees
that were due to REGENTS under the original Agreement and under Amendments #1, #2, and #3 thereto.

 

As consideration for the
addition of REGENTS' cases *** by way of this fourth amendment to the Agreement, LICENSEE shall also pay to REGENTS a non-creditable,
non-refundable fee of *** on or before *** and shall, within *** days after the final execution of this amendment #4 to the Agreement,
cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS employee(s) a total of *** shares of common
stock in KineMed, Inc., in accordance with the Shareholder's Agreements between REGENTS and LICENSEE attached hereto as Exhibit
A.

 

ARTICLE 5.1(c) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(c) For any of the
following U.C. Case Numbers: *** as described in Article 2.1(j) and in Article 1.1 (c) through (o) above, if the corresponding
patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number, LICENSEE shall be entitled
to a credit of *** toward its future royalty payments to REGENTS pursuant to Article 6.1.

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #4	Page 2	Confidential

    	 

    

  

ARTICLE 7.2 (DUE DILIGENCE) substitute
the following

 

7.2 (c) within *** after
the final execution date of this Agreement, LICENSEE shall have ***.

 

All remaining terms and conditions of the
Agreement (as amended) remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 
	 	 	 	 	 
	By	/s/ Carol Mimura	 	By	s/ James E. Burden
	 	Carol Mimura, Ph.D.	 	 	James E. Burden
	 	Director	 	 	COO & Secretary
	 	Office of Technology Licensing	 	 	 
	 	 	 	 	 
	Date	November 6, 2003	 	Date	November 6, 2003

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

    	Amendment #4	Page 3	Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]